Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Calcineurin Inhibitors
/ therapeutic use
Combined Modality Therapy
Cord Blood Stem Cell Transplantation
Disease-Free Survival
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease
/ etiology
Humans
Immunosuppressive Agents
/ therapeutic use
Incidence
Japan
/ epidemiology
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Mycophenolic Acid
/ therapeutic use
Myeloablative Agonists
/ therapeutic use
Retrospective Studies
Risk Factors
Transplantation Conditioning
/ methods
Treatment Outcome
Acute myeloid leukemia
Allogeneic hematopoietic cell transplantation
Cord blood transplantation
Elderly
Older patients
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
04
11
2020
accepted:
15
02
2021
pubmed:
25
2
2021
medline:
22
6
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
The availability of alternative donor sources could allow elderly patients to receive allogeneic hematopoietic cell transplantation (HCT). We retrospectively evaluated the outcomes of single-unit cord blood transplantation (CBT) in 1577 patients aged ≥60 years with acute myeloid leukemia (AML) in Japan between 2002 and 2017. In total, 990 (63%) patients were not in complete remission (CR) at the time of CBT. A myeloablative conditioning regimen (52%) and calcineurin inhibitor (CI) + mycophenolate mofetil (MMF)-based graft-versus-host disease (GVHD) prophylaxis (45%) were more commonly used. With a median follow-up for survivors of 31 months, the probability of overall survival and the cumulative incidence of leukemia-related mortality at 3 years was 31% and 29%, respectively. The cumulative incidence of non-relapse mortality (NRM) at 100 days and 3 years were 24% and 41%, respectively. The cumulative incidences of grade II-IV and grade III-IV acute GVHD at 100 days and extensive chronic GVHD at 2 years were 44%, 16%, and 14%, respectively. The cumulative incidence of neutrophil engraftment was 80% at 42 days. Results of multivariate analysis indicated that the following factors were significantly associated with higher overall mortality: performance status ≥1, hematopoietic cell transplantation-specific comorbidity index ≥3, adverse cytogenetics, extramedullary disease at diagnosis, and non-CR status at CBT. By contrast, female sex, HLA disparities ≥2, mycophenolate mofetil-based GVHD prophylaxis, and recent CBT were significantly associated with lower overall mortality. In conclusion, single CBT offers a curative option for AML patients aged ≥60 years with careful patient selection.
Identifiants
pubmed: 33624134
doi: 10.1007/s00277-021-04464-5
pii: 10.1007/s00277-021-04464-5
doi:
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Myeloablative Agonists
0
Mycophenolic Acid
HU9DX48N0T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1849-1861Subventions
Organisme : Japan Agency for Medical Research and Development, AMED
ID : 18ek0510023h0002
Références
Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 113:4179–4187
pubmed: 19008455
Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 119:3890–3899
pubmed: 22383796
pmcid: 3358248
Oran B, Weisdorf DJ (2012) Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 97:1916–1924
pubmed: 22773600
pmcid: 3590098
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood. 107:3481–3485
pubmed: 16455952
pmcid: 1895766
Yanada M, Naoe T (2012) Acute myeloid leukemia in older adults. Int J Hematol. 96:186–193
pubmed: 22791510
Hahn T, McCarthy PL Jr, Zhang MJ et al (2008) Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 26:5728–5734
pubmed: 18981462
pmcid: 2645611
Jagasia M, Arora M, Flowers ME et al (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 119:296–307
pubmed: 22010102
pmcid: 3251233
Flowers ME, Inamoto Y, Carpenter PA et al (2011) Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 117:3214–3219
pubmed: 21263156
pmcid: 3062319
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood Center (2010) Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 11:653–660
pubmed: 20558104
pmcid: 3163510
Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Najima Y, Fukuda T, Uchida N, Takahashi S, Nagamura-Inoue T, Morishima Y, Miyamura K (2016) Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 22:330–338
pubmed: 26476205
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, Witherspoon R, Mielcarek M, Deeg JH, Sorror M, Dahlberg A, Sandmaier BM, Salit R, Petersdorf E, Appelbaum FR, Delaney C (2016) Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 375:944–953
pubmed: 27602666
pmcid: 5513721
Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, Kanamori H, Hidaka M, Sakura T, Onizuka M, Kobayashi N, Sawa M, Eto T, Matsuhashi Y, Kato K, Ichinohe T, Atsuta Y, Miyamura K, Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation (2016) Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 91:E284–E292
pubmed: 26910296
Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A (2019) Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 6:e573–e584
pubmed: 31477550
Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, Matsumura T, Seo S, Matsuno N, Masuoka K, Kusumi E, Yuji K, Miyakoshi S, Matsuzaki M, Yoneyama A, Taniguchi S (2008) Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant. 14:583–590
pubmed: 18410901
Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ (2012) Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant. 47:494–498
pubmed: 21602900
Weisdorf D, Eapen M, Ruggeri A, Zhang MJ, Zhong X, Brunstein C, Ustun C, Rocha V, Gluckman E (2014) Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant. 20:816–822
pubmed: 24582782
pmcid: 4085692
Sandhu KS, Brunstein C, DeFor T, Bejanyan N, Arora M, Warlick E, Weisdorf D, Ustun C (2016) Umbilical cord blood transplantation outcomes in acute myelogenous leukemia/myelodysplastic syndrome patients aged ≥70 years. Biol Blood Marrow Transplant. 22:390–393
pubmed: 26415559
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D’Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 130:1156–1164
pubmed: 28674027
pmcid: 5580273
Konuma T, Kato S, Isobe M, Mizusawa M, Oiwa-Monna M, Takahashi S, Tojo A (2019) Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose total body irradiation/granulocyte colony-stimulating factor-combined cytarabine in single cord blood transplantation for elderly patients with nonremission myeloid malignancies. Biol Blood Marrow Transplant. 25:764–770
pubmed: 30529460
Ohta T, Sugio Y, Imanaga H, Oku S, Ohno Y (2019) Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. Int J Hematol. 110:347–354
pubmed: 31197737
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, Kato K, Tabuchi K, Tsuchida M, Morishima Y, Mitamura M, Kawa K, Kato S, Nagamura T, Takanashi M, Kodera Y (2007) Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 86:269–274
pubmed: 17988995
Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 103:3–10
pubmed: 26547570
Kanda J (2016) Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 103:11–19
pubmed: 26588927
Nakagawa R, Watanabe T, Kawano Y, Kanai S, Suzuya H, Kaneko M, Watanabe H, Okamoto Y, Kuroda Y, Nakayama T, the Chugoku-Shikoku Cord Blood Bank (2004) Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. Transfusion. 44:262–267
pubmed: 14962318
Takanashi M, Oba A, Ogawa A, Ito M, Kawahata Y, Nakajima K (2010) Red blood cell depletion of cord blood using an automated system -evaluation of the AXP system. Japanese Journal of Transfusion and Cell Therapy. 56:62–67
Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S (2019) Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplant. 54:1789–1798
pubmed: 31068659
Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, Ogawa H, Ohashi K, Ohno Y, Onishi Y, Aotsuka N, Nagamura-Inoue T, Kato K, Kanda Y, on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation (2013) Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 98:814–822
pubmed: 23349300
pmcid: 3640130
Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 15:825–828
pubmed: 7581076
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 28:250–259
pubmed: 1887253
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655
pubmed: 7165009
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 106:2912–2919
pubmed: 15994282
pmcid: 1895304
Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T, Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T, Ichinohe T, Atsuta Y, Yano S (2018) Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 59:601–609
pubmed: 28750566
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 15:367–369
pubmed: 19203728
pmcid: 3110087
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458
pubmed: 23208313
pmcid: 23208313
Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S (2016) A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 22:1844–1850
pubmed: 27345142
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, Kroger N, Mufti GJ, de Witte TM (2010) Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 28:405–411
pubmed: 20008642
McClune BL, Weisdorf DJ, Pedersen TL et al (2010) Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 28:1878–1887
pubmed: 20212255
pmcid: 2860368
Aoki J, Kanamori H, Tanaka MY et al (2016) Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol 91:302–307
pubmed: 26663096
Koreth J, Aldridge J, Kim HT, Alyea EP III, Cutler C, Armand P, Ritz J, Antin JH, Soiffer RJ, Ho VT (2010) Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 16:792–800
pubmed: 20074656
pmcid: 2866750
Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B (2011) Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 17:1796–1803
pubmed: 21699879
Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M (2012) Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 18:289–294
pubmed: 21781949
Brunner AM, Kim HT, Coughlin E, Alyea EP III, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB (2013) Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 19:1374–1380
pubmed: 23791626
Devine SM, Owzar K, Blum W et al (2015) Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 33:4167–4175
pubmed: 26527780
pmcid: 4658453
Rashidi A, Ebadi M, Colditz GA, DiPersio JF (2016) Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 22:651–657
pubmed: 26529178
Poiré X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socié G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A (2018) Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 103:256–265
pubmed: 29242299
pmcid: 5792270
Rashidi A, DiPersio JF, Westervelt P et al (2016) Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation? Leukemia. 30:1797–1799
pubmed: 27230239
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A (2018) Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 11:55
pubmed: 29661208
pmcid: 5902953
Ustun C, Le-Rademacher J, Wang HL et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 33:2599–2609
pubmed: 31073153
pmcid: 6842042
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A (2019) Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 25:1975–1983
pubmed: 31181255
Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro, Schroeder L, Pape L, Extermann M, van Besien K, Artz AS (2013) Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 19:429–434
Rodrigues M, de Souza PMR (2020) de Oliveira Muniz Koch L, et al. The use of comprehensive geriatric assessment in older patients before allologeneic hematopoietic stem cell transplantation: a cross-sectional study. J Geriatr Oncol. 11:100–106
pubmed: 31230926
Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS (2014) Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 99:1373–1379
pubmed: 24816237
pmcid: 4116837
Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J (2018) Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 53:565–575
pubmed: 29330399
Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL (2020) Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 26:189–196
pubmed: 31493541
Jayani R, Rosko A, Olin R, Artz A (2020) Use of geriatric assessment in hematopoietic cell transplant. J Geriatr Oncol. 11:225–236
pubmed: 31761694
Konuma T, Kanda J, Inamoto Y et al (2019) Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 95:343–353
Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M (2016) Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 22:134–140
pubmed: 26365153
Sanz J, Jaramillo FJ, Planelles D, Montesinos P, Lorenzo I, Moscardó F, Martin G, López F, Martínez J, Jarque I, de la Rubia J, Larrea L, Sanz MA, Sanz GF (2014) Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. Biol Blood Marrow Transplant. 20:106–110
pubmed: 24516896
Cunha R, Loiseau P, Ruggeri A, Sanz G, Michel G, PaolaIori A, Socié G, Arcese W, Picardi A, Dias de Heredia C, Rio B, Locatelli F, O'Brien TA, Yakoub-Agha I, Angel Diaz M, Milpied N, Bittencourt H, Pedro Souza M, Aljurf M, Charron D, Boudjedir K, Labopin M, Gluckman E, Rocha V (2014) Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplant. 49:24–29
pubmed: 23955634
Konuma T, Kato S, Ishii H, Takeda R, Oiwa-Monna M, Tojo A, Takahashi S (2015) HLA-DRB1 mismatch is associated with a decreased relapse in adult acute myeloid leukemia after single-unit myeloablative cord blood transplantation. Ann Hematol. 94:1233–1235
pubmed: 25754345
Yabe T, Azuma F, Kashiwase K et al (2018) HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation. Leukemia. 32:168–175
pubmed: 28652579
Terakura S, Kuwatsuka Y, Yamasaki S et al (2017) GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 52:1261–1267
pubmed: 28604665
Terakura S, Wake A, Inamoto Y et al (2017) Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 52:423–430
pubmed: 27941766
Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R (2013) Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 19:1183–1189
pubmed: 23676716
Newell LF, Flowers ME, Gooley TA et al (2013) Characteristics of chronic GVHD after cord blood transplantation. Bone Marrow Transplant. 48:1285–1290
pubmed: 23584444
pmcid: 3795867
Foster LW, McLellan L, Rybicki L, Dabney J, Copelan E, Bolwell B (2013) Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study. Bone Marrow Transplant. 48:671–677
pubmed: 23103681
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221
pubmed: 27276561
pmcid: 4979995
Molica M, Breccia M, Foa R, Jabbour E, Kadia TM (2019) Maintenance therapy in AML: the past, the present and the future. Am J Hematol. 94:1254–1265
pubmed: 31429099
Frisch A, Rowe JM, Ofran Y (2020; In press) How we treat older patients with acute myeloid leukaemia. Br J Haematol. 191:682–691
pubmed: 32352169